CONTEXT: Interindividual variation and tissue specificity of glucocorticoid (GC) sensitivity may occur in healthy subjects. OBJECTIVE AND PARTICIPANTS: The objective of this study was to evaluate the GC sensitivity in 40 healthy young subjects (21 women and 19 men; 22-42 yr old). DESIGN: We measured salivary and plasma cortisol levels before and after the administration of 0.25, 0.5, and 1 mg dexamethasone (DEX), given at 2300 h. We also evaluated the pattern of DEX-mediated inhibition of concanavalin A-stimulated peripheral blood mononuclear cell proliferation using different DEX doses, the number of binding sites, and the affinity of the GC receptor (Kd). RESULTS: The increasing DEX doses resulted in a dose-dependent decrease in cortisol levels. The majority of the subjects (70%) suppressed cortisol with DEX doses lower than 0.5 mg, and two did not suppress even with 1 mg DEX. The binding capacity was 4.1 +/- 0.3 fmol/mg protein, and the Kd was 8.1 +/- 1.3 nm. Four individuals presented with elevated Kd. Peripheral blood mononuclear cell proliferation was inhibited by DEX in a dose-dependent pattern. The median IC50 value was 7.1 x 10(-7) mol/liter. We found 77.5% (31 of 40) concordance among all three tests; 29 subjects showed all parameters between the 10th and 90th percentiles (P10-P90), one above P90, and one below P10. These two subjects could be classified as more GC resistant or sensitive, respectively. No concordance between in vivo and in vitro tests in two subjects suggested a tissue-specific sensitivity. CONCLUSIONS: This is the first report that, taking advantage of three bioassays performed on the same subject, demonstrated a considerable interindividual variability and tissue-specific GC sensitivity in a young healthy population.
CONTEXT: Interindividual variation and tissue specificity of glucocorticoid (GC) sensitivity may occur in healthy subjects. OBJECTIVE AND PARTICIPANTS: The objective of this study was to evaluate the GC sensitivity in 40 healthy young subjects (21 women and 19 men; 22-42 yr old). DESIGN: We measured salivary and plasma cortisol levels before and after the administration of 0.25, 0.5, and 1 mg dexamethasone (DEX), given at 2300 h. We also evaluated the pattern of DEX-mediated inhibition of concanavalin A-stimulated peripheral blood mononuclear cell proliferation using different DEX doses, the number of binding sites, and the affinity of the GC receptor (Kd). RESULTS: The increasing DEX doses resulted in a dose-dependent decrease in cortisol levels. The majority of the subjects (70%) suppressed cortisol with DEX doses lower than 0.5 mg, and two did not suppress even with 1 mg DEX. The binding capacity was 4.1 +/- 0.3 fmol/mg protein, and the Kd was 8.1 +/- 1.3 nm. Four individuals presented with elevated Kd. Peripheral blood mononuclear cell proliferation was inhibited by DEX in a dose-dependent pattern. The median IC50 value was 7.1 x 10(-7) mol/liter. We found 77.5% (31 of 40) concordance among all three tests; 29 subjects showed all parameters between the 10th and 90th percentiles (P10-P90), one above P90, and one below P10. These two subjects could be classified as more GC resistant or sensitive, respectively. No concordance between in vivo and in vitro tests in two subjects suggested a tissue-specific sensitivity. CONCLUSIONS: This is the first report that, taking advantage of three bioassays performed on the same subject, demonstrated a considerable interindividual variability and tissue-specific GC sensitivity in a young healthy population.
Authors: Rogier A Quax; Laura Manenschijn; Jan W Koper; Johanna M Hazes; Steven W J Lamberts; Elisabeth F C van Rossum; Richard A Feelders Journal: Nat Rev Endocrinol Date: 2013-10-01 Impact factor: 43.330
Authors: Shinwu Jeong; Nitin Patel; Christopher K Edlund; Jaana Hartiala; Dennis J Hazelett; Tatsuo Itakura; Pei-Chang Wu; Robert L Avery; Janet L Davis; Harry W Flynn; Geeta Lalwani; Carmen A Puliafito; Hussein Wafapoor; Minako Hijikata; Naoto Keicho; Xiaoyi Gao; Pablo Argüeso; Hooman Allayee; Gerhard A Coetzee; Mathew T Pletcher; David V Conti; Stephen G Schwartz; Alexander M Eaton; M Elizabeth Fini Journal: Invest Ophthalmol Vis Sci Date: 2015-04 Impact factor: 4.799
Authors: Richard J Santen; Christine M Jewell; Wei Yue; Daniel F Heitjan; Hershel Raff; Kevin S Katen; John A Cidlowski Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958
Authors: M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer Journal: Prog Retin Eye Res Date: 2016-09-22 Impact factor: 21.198
Authors: Christopher Burnsides; Jacqueline Corry; Jacob Alexander; Catherine Balint; David Cosmar; Gary Phillips; Jeanette I Webster Marketon Journal: J Inflamm Res Date: 2012-08-22